Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine Production

Dendritic cell [DC] vaccines can induce durable clinical responses, at least in a fraction of previously treated, late stage cancer patients. Several preclinical studies suggest that shielding programmed death-ligand 1 [PD-L1] on the DC surface may be an attractive strategy to extend such clinical b...

Descripción completa

Detalles Bibliográficos
Autores principales: Broos, Katrijn, Lecocq, Quentin, De Keersmaecker, Brenda, Raes, Geert, Corthals, Jurgen, Lion, Eva, Thielemans, Kris, Devoogdt, Nick, Keyaerts, Marleen, Breckpot, Karine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789804/
https://www.ncbi.nlm.nih.gov/pubmed/31394834
http://dx.doi.org/10.3390/vaccines7030085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789804/
https://www.ncbi.nlm.nih.gov/pubmed/31394834
http://dx.doi.org/10.3390/vaccines7030085

Ejemplares similares